Danaher Corporation (LON:0R2B)

London flag London · Delayed Price · Currency is GBP · Price in USD
206.02
+3.15 (1.55%)
At close: Aug 29, 2025
1.55%
Market Cap109.10B
Revenue (ttm)17.51B
Net Income (ttm)2.49B
Shares Outn/a
EPS (ttm)3.44
PE Ratio43.84
Forward PE25.04
Dividend0.66 (0.33%)
Ex-Dividend DateJun 27, 2025
Volume1,741
Average Volume923
Open206.81
Previous Close202.87
Day's Range204.76 - 207.00
52-Week Range171.02 - 280.17
Beta0.76
RSI47.44
Earnings DateOct 21, 2025

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment offers bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manuf... [Read more]

Industry Medical - Equipment & Services
Sector Healthcare
Founded 1969
Employees 63,000
Stock Exchange London Stock Exchange
Ticker Symbol 0R2B
Full Company Profile

Financial Performance

In 2024, Danaher's revenue was $23.88 billion, a decrease of -0.06% compared to the previous year's $23.89 billion. Earnings were $3.90 billion, a decrease of -17.79%.

Financial numbers in USD Financial Statements

News

mRNA Biotechs - Long-Term Value Risks Abound

mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery c...

1 day ago - Seeking Alpha

How Do Investors Really Feel About Danaher?

Danaher's (NYSE: DHR) short percent of float has risen 12.03% since its last report. The company recently reported that it has 9.47 million shares sold short , which is 1.49% of all regular shares th...

2 days ago - Benzinga

$1000 Invested In Danaher 10 Years Ago Would Be Worth This Much Today

Danaher (NYSE: DHR) has outperformed the market over the past 10 years by 1.07% on an annualized basis producing an average annual return of 13.56%. Currently, Danaher has a market capitalization of ...

7 days ago - Benzinga

EQUITY ALERT: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation – DHR

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential breaches of fiduciary duties by the directors and officers of Danaher Corporation ...

17 days ago - Business Wire

Analysts' Top S&P 500 Stocks to Buy Now

Broadcom, Microsoft and Amazon.com are just three names making the Street's list of top-rated stocks this month. Some of the other equities might surprise you.

22 days ago - Kiplinger

Danaher Stock Closes Near Day's High After Key Trading Signal

DHR reverses early down move after Alert Danaher Corp. (NYSE: DHR) experienced a Power Inflow today, a significant event for those who follow where smart money goes and value order flow analytics in ...

25 days ago - Benzinga

Danaher Stock Closes Near Day's High After Key Trading Signal

DHR reverses early down move after Alert

25 days ago - Benzinga

Danaher Appoints Jonathan Leiken as General Counsel

WASHINGTON , July 31, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a leading global life sciences and diagnostics innovator, today announced that Jonathan Leiken has been appointed Senior Vic...

4 weeks ago - PRNewsWire

Investors decided the good outweighs the bad with Danaher, says Jim Cramer

'Mad Money' host Jim Cramer talks how to play Danaher after earnings.

5 weeks ago - CNBC Television

Investors decided the good outweighs the bad with Danaher, says Jim Cramer

'Mad Money' host Jim Cramer talks how to play Danaher after earnings.

5 weeks ago - CNBC

Danaher Q2 2025 Update

5 weeks ago - Seeking Alpha

Danaher Stock: Attractively Valued And Poised For Growth Acceleration

Danaher Corporation thrives on bioprocessing demand & diagnostics resilience. Click for why, with solid execution & 80% recurring revenue, DHR offers upside.

5 weeks ago - Seeking Alpha

Danaher Raises 2025 Earnings Outlook

5 weeks ago - The Motley Fool

Danaher Lifts 2025 Earnings Outlook Amid Biotech Growth, Cost Discipline

Danaher Corp (NYSE: DHR) on Tuesday reported second-quarter 2025 sales of $5.94 billion, up 3.5% year-over-year, beating the consensus of $5.84 billion . The life science giant reported adjusted earn...

5 weeks ago - Benzinga

Cramer's Stop Trading: Danaher

Jim Cramer breaks down why he's keeping an eye on shares of Danaher.

5 weeks ago - CNBC Television

Cramer's Stop Trading: Danaher

Jim Cramer breaks down why he's keeping an eye on shares of Danaher.

5 weeks ago - CNBC

Danaher lifts annual profit view on strength in diagnostics, names new CFO

Life sciences firm Danaher raised its annual profit forecast on Tuesday, banking on resilient demand for its diagnostic testing tools and services.

5 weeks ago - Reuters

Danaher names new finance chief

5 weeks ago - Seeking Alpha

Danaher Announces Transition Plan for Chief Financial Officer

WASHINGTON , July 22, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a leading global life sciences and diagnostics innovator, today announced that Matthew Gugino, currently Group Chief Financi...

5 weeks ago - PRNewsWire